Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study Postmenopozal Osteoporoz Tedavisinde Denosumabin Etkinliǧi: Bir Yillik Takip, Tek Merkezli Çalisma
Turk Osteoporoz Dergisi, cilt.27, sa.3, ss.159-164, 2021 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.4274/tod.galenos.2020.83435
- Dergi Adı: Turk Osteoporoz Dergisi
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.159-164
- Anahtar Kelimeler: Denosumab, bone mineral density, postmenopausal osteoporosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: Denosumab is a humanized monoclonal antibody that targets the receptor activator of nuclear factor kappa-beta ligand. This study aimed to evaluate the effectiveness of denosumab, a new-generation drug, in treating postmenopausal osteoporosis (OP). Materials and Methods: The study included 15 postmenopausal OP patient files between July and September 2020. The effect of denosumab on bone mineral density (BMD) was evaluated using T-scores and gr/cm2 at the lumbar spine total, total hip, and femoral neck before the treatment and at the 12th month control. Results: After 1 year of treatment, total lumbar spine, femoral neck, and total hip T-scores significantly decreased, whereas total lumbar spine and total hip BMDs significantly increased (p=0.006, p=0.041, p=0.016, p=0.002, p=0.001, respectively). There was no statistically significant improvement in BMD in the femoral neck after 1 year of treatment (p=0.053). At the end of 1 year, total lumbar spine bone density increased by 17%, total hip bone density increased by 26%, and femoral neck bone density increased by 12%. Conclusion: Since OP is a global public health issue, long-term, randomized comparative studies with more patients are required.